Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of LY3502970 in Type 2 Diabetes Mellitus
NCT04426474Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised trial in type 2 diabetes mellitus (T2DM) comparing LY3502970 with Placebo (2 arms). Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug at Day 105. Started Oct 2020; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04426474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426474.